==> picture [244 x 451] intentionally omitted <==

Corum Group Limited

Q4 FY21 Cashflow and Activity Update

3 August 2021

Continued Positive Cashflow

==> picture [350 x 134] intentionally omitted <==

----- Start of picture text ----- $903$559$191($1,315)H1 FY20 H2 FY20 H1 FY21 H2 FY21----- End of picture text -----

Operating cashflow improvement has
- been a key focus for new Board and has delivered positive results in FY21
FY21 operating cashflow of $1.5m vs prior year operating cashflow loss of $(1.1)m
Receipts from customers have

continued to grow and are up 10% HoH, and up 42% YoY driven by the contribution from PharmX

==> picture [349 x 98] intentionally omitted <==

----- Start of picture text ----- $7.3$6.6$4.9 $4.8H1 FY20 H2 FY20 H1 FY21 H2 FY21----- End of picture text -----

Rationalisation of legacy products, decline in eCommerce real estate division and extended sales cycle due to Covid-19 led to flat receipts growth QoQ
Have invested progressively in new hires in Q4 and expect to see impact in next period

==> picture [58 x 25] intentionally omitted <==

1Adjusted to remove the impact of an R&D tax incentive credit received

$’000	H1 FY20H2 FY20	H1 FY21H2 FY21	FY20	FY21
Receipts from CustomersStaff Costs excluding one-off redundancy costsOther operating costsOne-off legal costs & restructuring costs	4,9354,837(3,864)(3,284)(1,839)(1,438)(548)75	6,6007,287(3,582)(3,367)(1,979)(2,111)(480)(906)	9,773(7,148)(3,277)(472)	13,887
				(6,949)
				(4,090)
				(1,386)
Net cash from / (used in) operating activities1	(1,315)191	559903	(1,124)	1,462
R&D tax incentive net of income tax paidNet cash from / (used in) investing activitiesNet cash from / (used in) financing activities	1,493-(1,666)(1,670)3,180(223)	1,700-(4,374)(1,812)7,415(236)	1,493(3,336)2,957	1,700
				(6,186)
				7,179
Total Cashflows	1,692(1,702)	5,299(1,145)	(10)	4,155

Operating cashflow improvement of +$2.6m compared to prior year, +230% primarily driven by the acquisition of PharmX
Operating cashflow excluding one-off legal and restructuring costs of $2.8m for the year, +$3.5m vs prior year
Investment into our Clear Suite of products and PharmX assets in the current year has been a core focus to drive future revenue growth. We are continuing this investment to grow our customer base and increase the value of our product offering.
Disciplined cost control has reduced staff costs YoY. This has allowed room for investment into the right skill sets to grow revenues.

==> picture [58 x 25] intentionally omitted <==

1Adjusted to remove the impact of an R&D tax incentive credit received

Regaining market share by targeting large groups through our relationships and Head Office product remains our focus
Growing PharmX through maximising the use of the platform with existing suppliers, onboarding additional suppliers and providing new added value services to all suppliers and stakeholders
Actively seeking value creating acquisitions

==> picture [58 x 25] intentionally omitted <==

==> picture [262 x 453] intentionally omitted <==

Contact: [email protected]